Full Breakdown
FDA Advisory Panel Recommends Expanding Peptide Compounding Amid Safety Concerns
7/25/2026, 11:24:45 AM
Core Event: Advisory Committee Votes to Allow Compounding of Select Peptides
During a two-day meeting on July 23 and July 24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that specialized compounding pharmacies be permitted to prepare several unapproved peptides. The panel approved the free-base and acetate forms of BPC-157, KPV and TB-500, as well as MOTS-c, epitalon and semax, while rejecting emideltide. The recommendations are non-binding; the FDA will consider them before issuing any final rule.
Background & Context
Peptides—short chains of amino acids—have become popular among wellness influencers and telehealth platforms, which market them for claims ranging from tissue repair to weight loss. In 2023 the FDA removed more than a dozen peptides from the list of substances that compounding pharmacies may prepare, citing potential safety risks. The restriction pushed many consumers to a gray market of “research-grade” products often sourced overseas. Health and Human Services Secretary Robert F. Kennedy Jr. has advocated reversing the ban, arguing that regulated compounding would move patients away from unsafe imports.
Data & Statistics
- Vote totals – BPC-157, KPV, TB-500: 8-6; MOTS-c: 7-5; epitalon: 8-5; semax: 8-4; emideltide: 7-6.
- Peptides under review – Seven compounds were evaluated for conditions such as ulcerative colitis, wound healing, obesity, insomnia and opioid withdrawal.
- Market estimates – Bloomberg cites a $2.2 billion opportunity for telehealth firms alone.
- Public input – The FDA received more than 1,900 comments during the meeting.
Official Statements & Responses
Emily Hilliard, spokesperson for the Department of Health and Human Services, said “All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.” Secretary Kennedy framed the recommendation as a step toward “restoring regulated access” and curbing the black market. FDA scientists warned that the chemical composition of the peptides is “not well characterized” and that safety and efficacy data are limited to animal studies and short-duration human trials.
Criticism & Opposition
Multiple FDA experts expressed alarm over the proposal, noting the lack of well-characterized chemical data and human safety studies.
Conflicting Reports & Gaps
- Market size – Bloomberg projects a $2.2 billion peptide market for telehealth platforms, while other sources describe the total market for the seven peptides as “worth billions of dollars” without a precise figure.
- Safety data – FDA staff highlight the absence of robust human studies, whereas proponents cite limited animal research and anecdotal reports as indicative of benefit.
Verbatim Quotes
- “I voted yes because it’s time to put this decision back in the hands of the patient, the physician, and the pharmacist,” — David Pope, chief pharmacy officer, Xifin Pharmacy Solutions
- “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science,” — Elizabeth Rebello, University of Texas MD Anderson Center
- “There’s no way to know what the substance actually is, was, or will be tomorrow because that name has no legal meaning,” — Russell Wesdyk, associate director, FDA’s drug center
What’s Next
The FDA will review the advisory panel’s recommendations, the staff’s opposing assessment, and the public comments before drafting a final rule. A formal rulemaking process, including a public comment period, is expected before any change to the compounding list takes effect.
